Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Editorial Volume 3 Issue 6

Maximum Possible Efforts by which we will Win Over this Deadly Pandemic of COVID-19

Kulvinder Kochar Kaur*

Scientific Director, DR Kulvinder Kaur Centre For Human Reproduction, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, DR Kulvinder Kaur Centre For Human Reproduction, Jalandhar, Punjab, India.

Received: April 22, 2020; Published: May 02, 2020


  Currently we are amidst the worldwide pandemic of a new type of Coronavirus (COVID-19) that is going on, and originated from Wuhan, China and has now spread to 140 other countries including Japan, Korea, Italy, USA and UK. The World Health Organization (WHO) declared that COVID-19 has assumed pandemic proportions, causing severe respiratory tract infections (RTI) in humans. Doubtfully this originated from bats and somehow mutated and adapted human transmission [1]. Structurally it is similar to SARS-CoV with The spike (S) glycoprotein of the Corona viruses being a class I viral fusion protein present on the outer envelope of the virion having a key role in viral infection by recognizing host cell receptors and modulating fusion of the viral as well as cellular membranes [2].



  1. Kulvinder Kochar Kaur., et al. “A Comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel corona virus syndrome –COVID-19”. Iberoamerican Journal of Medicine 2 (2020): 110-123.
  2. Song W., et al. “Cryo-EM structure of the SARS Coronavirus spike glyco protein in complex with its host cell receptor ACE2”. PLoS Pathogens8 (2018): e1007236.
  3. Wrapp D., et al. “Cryo-EM structure of the 2019-nCoV spike in the pre-fusion conformation”. Science6483 (2020): 1260-1263.
  4. To KK., et al. “Consistent detection of 2019 novel Coronavirus in saliva”. Clinical Infectious Diseases (2020).
  5. Xie X., et al. “Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT- PCR testing”. Radiology 12 (2020): 200343.
  6. Ai T., et al. “Correlation of chest CT and RT-PCR testing in Coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases”. Radiology 26 (2020): 200642.
  7. Xia W., et al. “Clinical and CT Features in Pediatric Patients With COVID-19 Infection: Different Points From Adults”. Pediatric Pulmonology 5 (2020): 1169-1174.
  8. Lechien JR., et al. “Olfactory and gustatory dysfunctions as a clinical presentation of mild-to moderate forms of the Coronavirus disease 2019 (COVID-19): A Multicenter European Study”. European Archives of Oto-Rhino-Laryngology (2020).
  9. Solaimanzadeh I. “Acetazolamide, nifedipine and phosphodiesterase inhibitors: Rationale for Their Utilization as adjunctive Countermeasures in the Treatment of Coronavirus disease 2019 (COVID-19)”. Cureus 3 (2020): e7343.
  10. Wilder Smith A and Freedman DO. “Isolation, quarantine, social distancing and community containment: pivotal role for old style public health measures in the novel Coronavirus (2019-nCoV) outbreak”. Journal of Travel Medicine 2 (2020).
  11. Chen N., et al. “Epidemiological and Clinical characteristics of 99 cases of Wuhan, China: a descriptive study”. Lancet 10223 (2020): 507-513.
  12. Zou X., et al. “Single cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable in 2019-nCoV Infection”. Frontiers of Medicine (2020).
  13. Dong L., et al. “Discovering drugs to treat Corona virus disease 2019 (COVID 19)”. Drug Discoveries and Therapeutics1 (2020): 58-60.
  14. Leon Caly., et al. “The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro”. Antiviral Research 178 (2020): 104787.
  15. Du L., et al. “The spike proteins of SARS-CoV-a target for vaccine and therapeutic development”. Nature Reviews Microbiology 3 (2009): 226-236.
  16. Mair-Jenkins J., et al. “The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of Severe Acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis”. Journal of Infectious Diseases 1 (2015): 80-90.
  17. Prather WR., et al. “Placental-derived and Expanded Mesenchymal Stromal Cells (PLX-I) to Enhance the Engraftment of Hematopoietic Stem Cells Derived from Umbilical Cord Blood”. Expert Opinion on Biological Therapy 8 (2008): 1241-1250.
  18. Uthay Kumar., et al. “Non-specific Effects of Vaccines Illustrated Through the BCG Example: From Observations to Demonstrations”. Frontiers in Immunology 9 (2018): 2869.


Citation: Kulvinder Kochar Kaur. “Maximum Possible Efforts by which we will Win Over this Deadly Pandemic of COVID-19". Acta Scientific Microbiology 3.6 (2020): 01-03.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US